EMA Recommends Extension of Therapeutic Indications for Acalabrutinib By Ogkologos - June 18, 2025 755 0 Facebook Twitter Google+ Pinterest WhatsApp A new indication concerns the treatment of adult patients with previously untreated CLL in combination with venetoclax Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Making Cancer Clinical Trials Available to More Patients March 7, 2019 Studies Assess Impact of Cancer Risk-Reduction Measures for People with BRCA... April 15, 2024 FDA Grants Accelerated Approval to Elranatamab-bcmm for Multiple Myeloma September 26, 2023 ESMO World Congress on Gastrointestinal Cancer 2020 June 22, 2020 Load more HOT NEWS Routes to a healthier shopping journey – how your supermarket environment... Targeted Therapy Cabozantinib Slows Progression of Rare Kidney Cancer ER-Low Positive Breast Cancer Shows Similar Clinical Behaviour and Response to... Do Birth Control Pills Impact My Cancer Risk?
